Pettyjohn Wood & White Inc. Acquires 387 Shares of Amgen, Inc. (NASDAQ:AMGN)

Pettyjohn Wood & White Inc. raised its holdings in Amgen, Inc. (NASDAQ:AMGN) by 14.0% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,160 shares of the medical research company’s stock after acquiring an additional 387 shares during the quarter. Pettyjohn Wood & White Inc.’s holdings in Amgen were worth $612,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Thompson Investment Management Inc. grew its position in Amgen by 1.1% in the 3rd quarter. Thompson Investment Management Inc. now owns 22,144 shares of the medical research company’s stock valued at $4,285,000 after acquiring an additional 247 shares during the last quarter. Unigestion Holding SA grew its position in shares of Amgen by 916.3% during the 3rd quarter. Unigestion Holding SA now owns 16,536 shares of the medical research company’s stock worth $3,200,000 after buying an additional 14,909 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of Amgen by 0.7% during the 3rd quarter. Daiwa Securities Group Inc. now owns 38,048 shares of the medical research company’s stock worth $7,362,000 after buying an additional 258 shares in the last quarter. First National Bank of Omaha grew its position in shares of Amgen by 2.9% during the 3rd quarter. First National Bank of Omaha now owns 27,133 shares of the medical research company’s stock worth $5,250,000 after buying an additional 776 shares in the last quarter. Finally, Benedict Financial Advisors Inc. grew its position in shares of Amgen by 1.2% during the 3rd quarter. Benedict Financial Advisors Inc. now owns 26,334 shares of the medical research company’s stock worth $5,096,000 after buying an additional 319 shares in the last quarter. 76.33% of the stock is currently owned by institutional investors.

A number of research firms have recently issued reports on AMGN. Piper Jaffray Companies increased their price target on Amgen from $210.00 to $218.00 and gave the stock an “overweight” rating in a research report on Monday, August 26th. Leerink Swann increased their price target on Amgen from $189.00 to $205.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Mizuho reissued a “hold” rating and set a $212.00 price target on shares of Amgen in a research report on Sunday, September 29th. Credit Suisse Group reissued an “outperform” rating and set a $225.00 price target (up previously from $202.00) on shares of Amgen in a research report on Friday, August 16th. Finally, Royal Bank of Canada reissued a “hold” rating on shares of Amgen in a research report on Monday, September 30th. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $219.56.

In other news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total value of $413,400.00. Following the completion of the transaction, the director now directly owns 16,336 shares in the company, valued at $3,376,651.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total value of $91,566.25. Following the completion of the transaction, the director now owns 5,413 shares of the company’s stock, valued at $1,166,230.85. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,851 shares of company stock valued at $3,685,674. 0.25% of the stock is currently owned by company insiders.

Amgen stock traded up $3.12 during midday trading on Friday, reaching $221.11. The company’s stock had a trading volume of 2,069,900 shares, compared to its average volume of 2,911,719. The stock’s 50-day simple moving average is $202.27 and its 200-day simple moving average is $188.68. The company has a debt-to-equity ratio of 2.54, a current ratio of 2.89 and a quick ratio of 2.59. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $221.25. The stock has a market capitalization of $127.80 billion, a P/E ratio of 15.35, a PEG ratio of 2.21 and a beta of 1.09.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, beating analysts’ consensus estimates of $3.53 by $0.13. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.63 billion. During the same period last year, the business posted $3.69 earnings per share. The firm’s revenue was down 2.8% compared to the same quarter last year. As a group, equities research analysts expect that Amgen, Inc. will post 14.44 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Friday, November 15th will be paid a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 2.62%. The ex-dividend date is Thursday, November 14th. Amgen’s dividend payout ratio (DPR) is presently 40.28%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: What is the Dividend Aristocrat Index?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.